Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. - Wikidata - wikimedia - TriplyDB

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

http://www.wikidata.org/entity/Q36653830

about

When and how do seizures kill neurons, and is cell death relevant to epileptogenesis?Cyclooxygenase-2 in epilepsy.Dual and Opposing Roles of MicroRNA-124 in Epilepsy Are Mediated through Inflammatory and NRSF-Dependent Gene Networks.The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Seizure burden is independently associated with short term outcome in critically ill children Systemic inflammation regulates microglial responses to tissue damage in vivo Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Lead optimization studies of cinnamic amide EP2 antagonists Prostanoid receptor EP2 as a therapeutic target Impairment of kindling development in phospholipase Cγ1 heterozygous mice.Development of second generation EP2 antagonists with high selectivity The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus Role of inflammatory mediators in the pathogenesis of epilepsy.Hippocampal neuro-networks and dendritic spine perturbations in epileptogenesis are attenuated by neuroprotectin d1.Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor, NS-398, after lithium pilocarpine-induced status epilepticus.Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus Candidate drug targets for prevention or modification of epilepsy Intracerebral hemorrhage outcomes following selective blockade or stimulation of the PGE2 EP1 receptor.EP2 Receptor Signaling Regulates Microglia Death.Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis.Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery Opposing roles of LTB4 and PGE2 in regulating the inflammasome-dependent scorpion venom-induced mortality.Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.EP2 receptor signaling pathways regulate classical activation of microglia.Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Does brain inflammation mediate pathological outcomes in epilepsy?Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.EP2 receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis.Neural circuit mechanisms of post-traumatic epilepsy.Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates.Disease modification in epilepsy: from animal models to clinical applications.Neuroinflammatory targets and treatments for epilepsy validated in experimental models.[18F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's Disease.Exploring novel AEDs from drugs used for treatment of non-epileptic disorders.

P2860

Q26824190-6378328D-9843-4284-8664-398DC7F10DAC Q26827095-BFD72DB7-5A50-4913-A9D5-8094D6D3BCBA Q27319868-804CEB3E-57AF-4903-8B9B-5AA57413A685 Q30576758-4930DB1D-C6CB-4A92-A88E-C17B4D95A860 Q30577004-D1628AC7-533B-4D79-B433-42AA53841978 Q30643015-1116A605-93F8-4564-A96A-46273E3C3299 Q33651797-A2AD0B36-1950-42F0-83F7-19392F8BB8BA Q33654575-972D5685-F26E-43F8-B4DF-7D63CF537A2E Q33711678-C0527C4F-9BEA-4211-B01F-67F43E1EF8F1 Q33715730-3C516250-DCD7-4CEE-9E43-74D9530EB83B Q33939410-1DF05EFD-49F9-4DF7-B5B7-A48380C3582A Q34036388-B22EB89C-9CC7-451C-88B1-426257FB80E8 Q34100649-2B2F35CB-CC66-4A88-BF28-54D3BAC66C03 Q35008940-FCAB73DD-0D1E-4B5B-AFBF-202211F77B66 Q35078392-B7F3DAB9-051B-47D6-9A83-AD80908E9265 Q35287263-9CC0282C-F628-427E-ACD1-122C8C2E43BE Q35534894-EE5B0716-BC96-466E-A74C-CAC0A9E36549 Q35594944-0E381556-3518-4822-A94F-7BA137E28B42 Q35732404-815EB198-7EF6-4FA1-843A-A090A1E1A8A4 Q35745955-134AE203-F802-4580-920C-B6503A877786 Q36380440-BB21EE57-4F73-4D7E-BE56-D4C8339F3341 Q36426301-A158473A-66F3-4CDB-BD40-81FE154F1349 Q36482822-5F0B4FD0-28E1-4C71-A053-E3E51564B1AC Q36615677-E9859EC0-9D34-4D24-99D6-39A718239222 Q36620651-40639AC8-9B5D-4E44-870D-AB1C9B008317 Q36725062-9D6F0EF1-B82A-4FF3-9FE1-F9CE1FEA408A Q36833728-AA8B0F85-5E00-4C81-8DF7-F8FA0E827367 Q36901520-2867FBF2-A980-4A8E-871E-C03A427050BC Q37063800-84744BCF-F7FE-42BE-96B5-3B3F1C1B3FF3 Q37208507-9AEC1DC9-A2EF-4500-89E1-F0CD76E99D79 Q37281455-F06D1D31-01A5-4B09-8C59-E0C3AC9AFF18 Q37340703-23C41AA2-1F90-4580-94F1-3172EC29D8F2 Q37350938-71138E17-6981-4B91-8186-E18CC84EA698 Q37692289-A61AC930-ECDE-4A5E-9E19-0FB521BAC76B Q38115775-880C0CBE-1791-46DB-B4A9-84CB8AAF23A1 Q38229056-A10CA6B1-1B20-4934-B900-CC4E51FF3C9E Q38450069-5B2B0615-1FE6-474E-8BDB-7E23D7AAC8D5 Q38662997-0D6D16B6-13A7-4800-87C2-7680AECB97FC Q38772065-57128455-2780-4409-BAF2-A2EE0FFD8477 Q38787286-E6BA33CD-3828-4422-9BB1-6EB607D94E62

P2860

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

http://www.wikidata.org/entity/Q36653830

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Inhibition of the prostaglandi ...... tality and brain inflammation.

@ast

Inhibition of the prostaglandi ...... tality and brain inflammation.

@en

type

label

Inhibition of the prostaglandi ...... tality and brain inflammation.

@ast

Inhibition of the prostaglandi ...... tality and brain inflammation.

@en

prefLabel

Inhibition of the prostaglandi ...... tality and brain inflammation.

@ast

Inhibition of the prostaglandi ...... tality and brain inflammation.

@en

P1433

Q36653830-6081C152-1C8B-45B0-BE95-069DAAC17B85

P1476

Q36653830-09491CEC-937B-4A9F-8F21-C79492761F68

P2093

Q36653830-3ED5F8B4-DAEA-47F5-8534-B3689A9F30A2

Q36653830-4FE4314D-B0B7-4272-8019-9F9E38D3EFF0

Q36653830-6714E0D7-0870-4684-964F-EBDA9CA7C866

Q36653830-6CCF2C8A-1DB1-4235-B5E0-94C62A58F85F

Q36653830-B3E59DBB-3074-478F-A0CC-0090BCDCD3BF

Q36653830-FE36AF3D-2C63-4765-B5C3-DADCA72D387F

P2860

Q36653830-05A75156-175C-4B12-9523-E5FEF56608D2

Q36653830-12B73443-C1ED-48FD-8F4C-C49EB17D7F93

Q36653830-14D440DB-E1D1-4CAE-A6A1-65028626195A

Q36653830-18DE7F11-3CA6-411D-8AE6-8A6FD5FF18F0

Q36653830-214C3ADB-89CC-4767-A81B-D672E75D1F7E

Q36653830-256EF9BD-3393-4D15-B38F-02B9A03886ED

Q36653830-26304E79-47FC-43A5-AC93-884A75CEC924

Q36653830-2AD310DB-A316-4BF6-8068-9858FE543CDC

Q36653830-2B7B5EDB-A8F1-4C39-BC6D-EA2D4F0DA316

Q36653830-2E49D503-6A3C-4381-ADE4-C6B33FF32B28

P304

Q36653830-FD223B7F-101D-42FF-9E1F-B0886C2A069E

P31

Q36653830-C4C28716-FA3E-45C1-B331-53E2CF2D4332

P356

Q36653830-D1487FD4-D87A-44D4-BB2E-C026563FB755

P407

Q36653830-EC04DD96-0368-442A-824E-FD715BF20EF2

P433

Q36653830-885A00DD-4630-45AC-8245-E46B25E67A93

P478

Q36653830-937253FC-4332-486D-A8D8-64EE572D2729

P577

Q36653830-1DF9E403-50E8-4E1C-B7EB-653315200B38

P5875

Q36653830-9DD1B47C-4342-4D8F-98F2-8D6A5DD51B84

P698

Q36653830-FCBDAB31-974E-40BD-B414-1F9F28DB24C0

P921

Q36653830-C6A1D007-D534-405E-85DC-B6118D8F3294

P932

Q36653830-C65CB53C-6988-42C9-BB3C-C9A84181FE09

P356

PNAS.1218498110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inhibition of the prostaglandi ...... tality and brain inflammation.

@en

P2093

F Edward Dudek

http://www.w3.org/2001/XMLSchema#string

Jianxiong Jiang

http://www.w3.org/2001/XMLSchema#string

Raymond Dingledine

http://www.w3.org/2001/XMLSchema#string

Thota Ganesh

http://www.w3.org/2001/XMLSchema#string

Wendy A Pouliot

http://www.w3.org/2001/XMLSchema#string

Yi Quan

http://www.w3.org/2001/XMLSchema#string

P2860

Management of refractory status epilepticus in adults: still more questions than answers

Brain tissue injury and blood-brain barrier opening induced by injection of LGE2 or PGE2

Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity

Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor.

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus.

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

Emerging roles of PGE2 receptors in models of neurological disease.

Comparisons of the mortality and clinical presentations of status epilepticus in private practice community and university hospital settings in Richmond, Virginia.

Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity.

P304

3591-3596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1218498110

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235524262

http://www.w3.org/2001/XMLSchema#string

P698

23401547

http://www.w3.org/2001/XMLSchema#string

P921

status epilepticus

P932

3587237

http://www.w3.org/2001/XMLSchema#string